The authors assessed the effect of sodium valproate, which is thought to
elevate brain gamma-aminobutyric acid (GABA) levels, in the treatment of
Huntington's disease by an objective ultrasound method in three patients
with Huntington's disease. Despite plasma levels ranging from 47.0 to 140.8
microgram/ml (mean, 104.7), sodium valproate had no beneficial effect on
involuntary movements. The authors stress the importance of activation to
achieve a standard level of arousal in the assessment of involuntary
movements.
Abstract Teaser